Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) Financial Review

Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Volatility and Risk

Atyr PHARMA has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Insider & Institutional Ownership

61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by company insiders. Comparatively, 20.6% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Atyr PHARMA and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
MiNK Therapeutics	N/A	N/A	-189.14%

Analyst Recommendations

This is a summary of recent ratings and price targets for Atyr PHARMA and MiNK Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0	0	6	1	3.14
MiNK Therapeutics	0	0	2	0	3.00

Atyr PHARMA presently has a consensus price target of $18.60, suggesting a potential upside of 522.07%. MiNK Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 383.87%. Given Atyr PHARMA’s stronger consensus rating and higher probable upside, equities analysts plainly believe Atyr PHARMA is more favorable than MiNK Therapeutics.

Valuation and Earnings

This table compares Atyr PHARMA and MiNK Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$235,000.00	1,130.59	-$50.39 million	($0.87)	-3.44
MiNK Therapeutics	N/A	N/A	-$22.46 million	($2.92)	-2.65

MiNK Therapeutics has lower revenue, but higher earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Atyr PHARMA beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.